The global brachytherapy afterloaders market size was USD 904.4 Million in 2022 and is likely to reach USD 1.67 Billion by 2031, expanding at a CAGR of 7.1% during 2023–2031. The market growth is attributed to the increasing prevalence of cancer augments.
Brachytherapy is a type of cancer treatment that involves the placement of a radioactive source inside or close to the tumor. This technique allows for the delivery of a high dose of radiation directly to the cancerous tissue while minimizing exposure to the surrounding healthy tissue.
During brachytherapy, a doctor places small, radioactive pellets, or seeds into or near the cancerous tissue. The radioactive material is inserted directly into the tumor needles or catheters, or it may place into a body cavity such as the vagina or rectum close to the tumor. The radioactive material is left in place for a set period, depending on the type and stage of the cancer being treated.
Brachytherapy is used to treat various types of cancer including breast cancer, eye cancer, brain cancer, rectal cancer, head & neck cancer, cervical cancer, and others. It is often used for other treatments such as surgery or chemotherapy, to improve the chances of a cure. Brachytherapy is generally considered a safe and effective treatment option for many types of cancer. Sometimes it is used to treat other conditions such as heart problems.
Brachytherapy uses low dose rate (LDR) and high dose rate (HDR) techniques and it depends on the time the radioactive sources continue in place. There is an advantage of brachytherapy, where patients typically make few visits to the radiotherapy clinic as compared with external beam radiation therapy (EBRT). This makes treatment accessible and convenient for patients.
The market report finds that the COVID-19 pandemic has negatively impacted the growth of the brachytherapy afterloaders market. It simultaneously impacts the healthcare sector, especially in cancer treatment and delays were getting standard care to patients.
Brachytherapy Afterloaders Market Dynamics
The global brachytherapy afterloaders market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance during 2023 to 2031.
Major Drivers
The increasing prevalence of cancer among the population is driving the growth of the brachytherapy afterloaders market. According to, the World Health Organization (WHO) report, cancer is the leading cause of death all over the world, accounting for nearly 10 million deaths in 2020, or nearly one in sixths.
The most common cancers are lung, breast, colon & rectum, and prostate cancers. However, the geriatric population and increasing adoption of brachytherapy among cancer therapy treatments are expected to boost the market.
Existing Restraints
The high cost of brachytherapy and unfavorable reimbursement policies for brachytherapy are expected to restrain the market. The lack of trained radiation oncologists is another factor that may hamper the growth of the brachytherapy afterloaders market.
Emerging Opportunities
The need for cancer treatment is expected to offer lucrative opportunities for the market players. Each cancer type requires unique treatment which offers opportunities for the market.
Scope of Brachytherapy Afterloaders Market Report
The report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Brachytherapy Afterloaders Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2020–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Application (Breast Cancer, Prostate Cancer, Cervical Cancer, and Others) and Technique (Low Dose Rate Afterloader and High Dose Rate Afterloader)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Elekta; Eckert & Ziegler; Varian Medical Systems, Inc.; Panacea Medical Technologies Pvt. Ltd.; GE HealthCare.; Best Medical International, Inc.; IsoAid; C. R. Brad, Inc.; Piramal Enterprises Ltd.; BEBIG Medical.; and BIOMÉRIEUX
|
Brachytherapy Afterloaders Market Segment Insights
Application Segment Analysis
Based on application, the brachytherapy afterloaders market is divided into breast cancer, prostate cancer, cervical cancer, and others. The prostate cancer segment is expected to expand at a significant growth rate during the projection period.
It is the most common cancer among men. According to, the American Cancer Society’s estimates for prostate cancer in the United States for 2023 are about 288,300 new cases of prostate cancer and about 34,700 deaths from prostate cancer.
Technique Segment Analysis
On the basis of technique, the global market is segregated into low dose rate afterloader and high dose rate afterloader. The high dose rate (HDR) afterloader segment is expected to register a robust growth rate during the forecast period, owing to the increased healthcare suppliers. HDR is a single radioactive source that is placed inside the tumor for a few minutes and then removed.
It is most commonly used to treat head & neck, prostate, and cervical cancers. The low dose rate (LDR) after loader segment is projected to register a considerable CAGR during the forecast period, owing to the low-cost effectiveness during the entire procedure. The radioactive sources are positioned inside the tumor for a minimum of days but it is left in position permanently. It is most commonly used to treat prostate cancer and brain tumors.
Regional Analysis
In terms of region, the global brachytherapy afterloaders market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the increasing adoption of innovative technology and increase in funding for research & development (R&D) for cancer treatment.
The increasing number of surgeries is boosting the market in the region. Asia Pacific is anticipated to expand at a rapid pace in the coming years, due to the increase in healthcare research and the rising geriatric population susceptible to various cancer diseases.
Segments
The global brachytherapy afterloaders market has been segmented on the basis of
Application
- Breast Cancer
- Prostate Cancer
- Cervical Cancer
- Others
Technique
- Low Dose Rate Afterloader
- High Dose Rate Afterloader
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Elekta
- Eckert & Ziegler
- Varian Medical Systems, Inc.
- Panacea Medical Technologies Pvt. Ltd.
- GE HealthCare
- Best Medical International, Inc.
- IsoAid
- C. R. Brad, Inc.
- Piramal Enterprises Ltd.
- BEBIG Medical.
- BIOMÉRIEUX
Competitive Landscape
Key players competing in the global brachytherapy afterloaders market are Elekta; Eckert & Ziegler; Varian Medical Systems, Inc.; Panacea Medical Technologies Pvt. Ltd.; GE HealthCare.; Best Medical International, Inc.; IsoAid; C. R. Brad, Inc.; Piramal Enterprises Ltd.; BEBIG Medical.; and BIOMÉRIEUX
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
Request For Customization
Enquiry Before Buying
Speak With Analyst
